17,261 trials
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI…
Bladder Cancer
Primary: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate — 8; 10; 20; 17 Participants — p=0.1
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
Lichen Planopilaris · Frontal Fibrosing Alopecia
Primary: Change in Patient-Reported Itch — -0.33 units on a scale
Advanced Adult Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Recurrent Adult Hepatocellular Carcinoma
Primary: Median Progression Free Survival (PFS) — 10.32 months
Dry Eye Disease
Primary: Mean Change in Goblet Cell Area — -38.8; -6.7 um
Ovary Cancer · Cervix Cancer · Endometrium Cancer
Primary: Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events — 3; 3; 3; 3 Participants
Osteoarthritis, Knee
Primary: Change From Baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale (WOMAC-A) Score in Patients Receiving a Single Dose…
Hepatocellular Carcinoma
Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536
Fatty Liver, Nonalcoholic · NAFLD · Nonalcoholic Fatty Liver Disease
Primary: Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF — -2.918; -4.829; -1.962 Change in percentage of liver fat — p=0.199
Smoking Cessation
Primary: Rates of Prolonged Smoking Abstinence — 11; 7 Participants
Breast Cancer
Primary: Overall Response Rate — 1 Participants
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Events — 123; 29; 100; 49 Events
Ependymoma · Anaplastic Ependymoma
Primary: Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year — 76.4 Percentage of participants
Benign Breast Neoplasm · Ductal Breast Carcinoma In Situ · Invasive Breast Carcinoma
Primary: Normal Breast Tissue Expression of Tumor Necrosis Factor Alpha (TNF-alpha) Levels — 0.26; 0.08; 0.06; 0.16 Log Transformed Relative ExpressionLevel — p=.50